INTRODUCTION
Histoplasmosis is a systemic fungal infection caused by the intracellular dimorphic fungus Histoplasma capsulatum. It is endemic in the USA, but has been reported in South America and Africa. 1, 2 Clinical presentation of histoplasmosis is nonspecific, and 95% of the patients with H. capsulatum infections are asymptomatic. Therefore, the clinical presentation of histoplasmosis may vary from asymptomatic to disseminated disease depending on the patient's immunological status. [3] [4] [5] Histoplasmosis is an AIDS-defining opportunistic infection presenting as an invasive form. [6] [7] [8] Immune reconstitution inflammatory syndrome (IRIS)-related dermatological manifestations of HIV are common, and cutaneous histoplasmosis following antiretroviral therapy (ART) was previously described. 9, 10 We report the case of an HIV-infected patient who presented with cutaneous histoplasmosis 4 months after the onset of ART, with viral suppression and immunological recovery, which were consistent with Article / Clinical Case Report an IRIS event. The clinical manifestations, diagnosis, and management of histoplasmosis IRIS are reviewed.
CASE REPORT
A 43-year-old male, known to be HIV infected for 6 months, was referred by his primary HIV clinic to the Mulago National Referral Hospital in Uganda with a 2-month history of nodular lesions in the face. Skin findings were also associated with a nonproductive cough, dyspnea, and fever over the past month. The skin nodules started to appear 2 months after ART was initiated, and began as small lesions on the nose that progressed in size and number throughout the face. The patient was initially and empirically treated with azithromycin with the hypothesis of atypical Mycobacterium cuneiform infection, with mild clinical improvement. The patient was started on ART (tenofovir 300 mg/day, lamivudine 300 mg/day, and efavirenz 600 mg/day) and trimethoprim/sulfamethoxazole for prophylaxis at the time of HIV infection diagnosis.
His past medical history included the diagnosis of HIV infection 6 months earlier, with a nadir CD4 determination of 42 cells/mm 3 .
On examination, his general condition was fair, with no lymphadenopathy, normal vital signs, and a clear chest exam. Skin examination showed hyper-pigmented nodular lesions on his face with varying diameters. The larger lesions (approximately 2 cm × 3.5 cm) were on the nose (Figure 1 ). The abdominal examination did not reveal hepatosplenomegaly.
The patient's chest x-ray was normal; thoracic computed tomography was not performed. Laboratory investigations revealed normal hematological indices and serum electrolytes.
The serological test for HIV was positive. The viral load for HIV was undetectable, and CD4 was 108 cells/mm 3 . Diagnoses of Kaposi sarcoma, bacillary angiomatosis, squamous cell carcinoma, and invasive mycosis were considered. A punch biopsy was obtained from two lesions of the face. Histological examination showed granulomatous dermatitis with round cytoplasmic organelles within the macrophages consistent with H. capsulatum var. capsulatum ( Figure 2 and Figure 3 ).
A diagnosis of unmasking mucocutaneous histoplasmosis IRIS was made. The patient was started on intravenous amphotericin B (1 mg/kg) daily and oral itraconazole (400 mg daily) for 2 weeks, besides potassium and magnesium supplementation, paracetamol, and 3 L of intravenous saline daily during hospitalization. Antiretroviral therapy was continued. The patient's renal function and complete blood count remained within normal ranges during the course of amphotericin.
On completion of the amphotericin treatment, the patient's symptoms regressed and he was discharged after 14 days on oral fluconazole 400 mg daily, as he could not afford the high cost of itraconazole. The patient has been monitored monthly since hospital discharge and continues to improve on fluconazole therapy and ART. His clinical status is favorable; the skin lesions are healing but leaving enduring scarring and partial destruction of the nasal cartilage ( Figure 4 ).
DISCUSSION
Histoplasmosis is a common AIDS-defining illness 11 caused by H. capsulatum, a dimorphic fungus, which is distributed worldwide and is endemic in both South and North America, particularly in the Ohio and Mississippi river valleys in the latter. H. capsulatum var. capsulatum and H. capsulatum var. duboisii are the variants that cause human disease. 12, 13 H. capsulatum var. duboisii is described only in Africa; however, both variants are endemic in Uganda. Spores of H. capsulatum are found in the soil and caves inhabited by birds and bats. 4 Primary lung infection results from the inhalation of microconidia, which turn into yeast in the lungs. The yeast is then spread to the reticuloendothelial system within 2-3 weeks by tissue macrophages. 5, 14 The clinical presentation of histoplasmosis depends on the integrity of the immune system. Nearly 95% of the infected people with normal immune systems will remain asymptomatic, 1, 15 and the remaining will present acute or chronic pulmonary histoplasmosis. 15 However, individuals with immunosuppressive disorders affecting cell-mediated immunity may present with disseminated histoplasmosis. HIV-infected people with a CD4 cell count below 100 cells/mm 3 are at increased risk for the development of disseminated histoplasmosis, 14, 15 which was the case with our patient, who had a CD4 cell count of 42 cells/mm 3 . Cutaneous presentation is found in 6% of patients with disseminated histoplasmosis. 5, 16, 18 However, mucocutaneous involvement varies by geographic location and occurs more commonly in AIDS patients, particularly in those with suspected IRIS. 9, 19 A review of the clinical manifestations of disseminated histoplasmosis showed that the dermatological manifestation was more common and more extensive in Brazilian HIV-infected people when compared with North American counterparts. 9 A similar tropism for skin and lymph nodes involvement has been observed in African histoplasmosis. Nacher et al. 20 described a higher incidence of disseminated histoplasmosis among patients that recently started on antiretroviral therapy, suggesting that this treatment can lead to unmasking IRIS. Passos et al. 21 reported the case of paradoxical histoplasmosis IRIS following re-introduction of HAART in a Brazilian patient that voluntarily stopped his HAART and itraconazole prophylaxis. Breton et al. 22 presented four patients with HIV-associated with unmasking and paradoxical disseminated histoplasmosis IRIS. At the time of presentation, our patient was on ART for 4 months, with immunological response and viral suppression, which are features consistent with unmasking IRIS. 23, 24 Diverse diagnostic modalities with varying sensitivity and specificity are available for the diagnosis of histoplasmosis, including tissue cultures, fungal stains, and serologic tests for detecting antibodies or antigens. 5 Isolation of the pathogen in culture media (BACTEC™, Becton Dickinson, Sabouraud's agar) is the gold standard for the diagnosis; however, the isolation takes more than 4 weeks, which limits its clinical applicability. 25, 26 Culture specimens can be obtained from urine, blood, sputum, lymph nodes, bronchoalveolar lavage, or bone marrow aspirate. Serology, although rapid and sensitive, is limited by low specificity because of the cross-reactivity with other fungi. Moreover, serology shows reduced sensitivity in disseminated histoplasmosis and immune suppressed patients, and the antibodies remain elevated for an extended time, limiting its use for differentiating relapse from an earlier infection. [25] [26] [27] Urinary antigen testing offers rapid diagnosis with the sensitivity of 90% for patients with disseminated histoplasmosis and can be used for monitoring the response to therapy. 2, 25 Assays of histoplasma antigen in our patient's body fluids were not performed as they are not readily available in Uganda.
Histological examination with the aid of Giemsa, Wright, the periodic acid of Schiff (PAS), or methenamine silver stainings provides a less expensive and rapid diagnosis, but has loose sensitivity for the antigenic tests. H. capsulatum appears in macrophages as ovoid or spherical uninucleate yeasts of 2-4 micrometers with narrow base buds. 5 Pneumocystis jiroveci, Toxoplasma gondii, Penicillium marneffei, Candida glabrata, Leishmania donovani, and Cryptococcus neoformans may appear similar to H. capsulatum on direct microscopy. However, most of the serologic tests are expensive and barely available in Uganda. In our case, the diagnosis was based on the histologic examination of the skin biopsy.
Our patient received amphotericin B and itraconazole for 2 weeks, which is the regimen of choice for the management of disseminated histoplasmosis where liposomal or lipid formulations of amphotericin are not available. 5, 15 The Infectious Diseases Society of America guidelines recommend that patients with disseminated histoplasmosis and HIV should be treated with amphotericin B (0.7-1 mg/kg per day) for 2 weeks followed by itraconazole for at least 12 months. 15 Secondary prophylaxis with itraconazole maintenance therapy (200 mg/day) should be considered for extended periods of immunosuppression. Some literature data suggest withdrawing prophylaxis at CD4 > 150 cells/mm 3 . 12, 28 Upon discharge, this patient was started on fluconazole instead of itraconazole because of the cost of the treatment and the unavailability of free dispensing of itraconazole in Uganda. Although fluconazole has some activity against histoplasmosis, it is less efficacious than itraconazole, and has been associated with higher resistance rates. [29] [30] [31] Antiretroviral therapy substantially improves the outcomes of HIV-infected people with disseminated histoplasmosis. Additionally, there is evidence suggesting that patients on ART who develop disseminated histoplasmosis IRIS should continue on the ART. [32] [33] [34] Literature data recommend continuing prophylaxis until the clinical and the laboratory results normalize. 29 Our patient received fluconazole 400 mg daily and was monitored monthly in the outpatient clinic. We intend to taper the dose of fluconazole to 200 mg at the twelfth week and withdraw it when the CD4 count exceeds 150 cells/mm 3 and, if available, a normal laboratory antigen assay is achieved. Although our patient is showing immunological improvement, there is a risk of relapse since he is receiving a less suitable drug. Additional studies are needed concerning the management and length of treatment of histoplasmosis with fluconazole to provide a second choice where itraconazole remains prohibitively expensive. We also recommend that clinicians should consider a diagnosis of cutaneous histoplasmosis in HIV-infected persons that present with Kaposi sarcoma-like lesions.
Note: The patient signed an informed consent authorizing the publication the pictures of his face.
